We investigated the effect of inhaled glucocorticoid (GC) on @entity2488 and on bronchial lability in schoolchildren born preterm. Twenty-one @entity1 with @entity2488 , increased responsiveness to a beta2-agonist, and/or increased diurnal variation in peak expiratory flow (PEF) were selected for an open longitudinal study of the value of inhaled GC. None of these @entity1 had an earlier diagnosis of @entity565 or current GC treatment. Eighteen @entity1 with median (range) birth weight 1025 (640-1600) g and gestational age 28 (24-35) weeks, age at study 10.1 (7.7-13) years, were treated with inhaled @entity4184 in initially high (0.8 mg m(-2) day(-1) for 1 month) and subsequently lower dose (0.4 mg m(-2) day(-1) for 3 months). Daily symptom scores were recorded. Spirometric values were measured in the clinic at the beginning and end of each treatment period. At home, @entity1 used a data storage spirometer. After treatment with @entity4184 for 4 months, spirometric values in the clinic did not significantly change. The median forced expiratory volume in 1 sec (FEV1) was 74% of predicted both at entry and after @entity4184 treatment. However, the median number of > or = 20% diurnal change in PEF values at home decreased during treatment. According to the present study, inhaled @entity4184 for 4 months had no significant effect on basic lung function but may decrease bronchial lability in schoolchildren born preterm.

Effect of inhaled XXXX therapy on lung function in schoolchildren born preterm.

@entity1 :: ('9606', 'Species') :: ['children'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity4184 :: ('MESH:D019819', 'Chemical') :: ['budesonide'] @entity2488 :: ('MESH:D001982', 'Disease') :: ['bronchial obstruction']
@entity4184 :: (MESH:D019819,Chemical) :: ['budesonide']
